Keyphrases
Relapsed or Refractory
100%
Myeloid Malignancies
100%
Azacitidine
100%
Bromodomain
100%
PLX51107
100%
Myelodysplastic Syndrome
50%
Protein Level
33%
Acute Myeloid Leukemia
33%
High Risk
33%
Combination Therapy
33%
Relapsed or Refractory Acute Myeloid Leukemia
33%
B-cell Lymphoma 2 (Bcl-2)
33%
Cyclin-dependent Kinase 6 (CDK6)
33%
HEXIM1
33%
Bromodomain and Extra-terminal Domain
33%
Clinical Data
16%
Leukemia
16%
Treatment Outcome
16%
Resistance Mechanisms
16%
MRNA Expression
16%
Heavily Pretreated Patients
16%
Phase I Trial
16%
Clinical Benefit
16%
Complete Remission
16%
Mononuclear Cells
16%
Gene Rearrangement
16%
Platelet Recovery
16%
Febrile Neutropenia
16%
Bcl-xL
16%
Immunoblot Analysis
16%
Overall Response Rate
16%
TP53 mutation
16%
C-Myc
16%
Pneumonia
16%
Preclinical Data
16%
Nonhematologic
16%
Patient Cohort
16%
Hypomethylating Agents
16%
Leukemia Risk
16%
High-risk Myelodysplastic Syndrome
16%
Hematologic Improvement
16%
CDKN1A
16%
Data Treatment
16%
IL-7R
16%
MECOM
16%
Severe Hyperbilirubinemia
16%
RNA-seq Analysis
16%
Free State
16%
CD93
16%
Bromodomain-containing Protein 4 (BRD4)
16%
Venetoclax
16%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Myelodysplastic Syndrome
100%
Myeloid Malignancy
100%
Azacitidine
100%
Combination Therapy
50%
Morphology
25%
Leukemia
25%
Messenger RNA
25%
Phase I Trials
25%
Immunoblotting
25%
Platelet
25%
Febrile Neutropenia
25%
Downregulation
25%
Upregulation
25%
Mononuclear Cell
25%
Oncogene C Myc
25%
Gene Rearrangement
25%
Hyperbilirubinemia
25%
Hypomethylating Agent
25%
RNA Sequence
25%
MDS1 and EVI1 Complex Locus Protein
25%
Venetoclax
25%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Myelodysplastic Syndrome
100%
Azacitidine
100%
Combination Therapy
50%
Western Blot
25%
Messenger RNA
25%
Leukemia
25%
Phase I Trials
25%
Remission
25%
Febrile Neutropenia
25%
Hyperbilirubinemia
25%
RNA-Sequencing
25%
MDS1 and EVI1 Complex Locus Protein
25%
Venetoclax
25%